| Name | Title | Contact Details |
|---|
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy with 28 years of innovative excellence and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. BioPlus earned a #1 patient satisfaction ranking in both oncology and hepatitis C in Zitter`s Specialty Pharmacy Patient Satisfaction Survey. Our RxExpress program moves each prescription through our system in the most streamline way. From the 2-Hour Patient Acceptance Guarantee at the beginning to the 2-Day Ready 2 Ship at the end, along with free overnight shipping, physicians and patients can trust BioPlus to provide effective service that`s delivered fast. By keeping the wait time for medications as short as possible, patients don`t have to wait to get back to living their lives. BioPlus provides a complete range of specialty services, including for cancer, hepatitis C, multiple sclerosis, rheumatoid arthritis, dermatology, and other complex, chronic conditions. We are a privately-held, pharmacist-owned company based in Altamonte Springs, Florida and accredited by URAC, VIPPS, and ACHC with a Distinction in Oncology.`
Clever Leaves is a multi-national cannabis company with a mission to operate in compliance with federal and state laws and with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabinoid business. With operations and investments in Canada, Colombia, Germany, Portugal, and the United States, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry`s leading global cannabinoid companies recognized for its principles, people, and performance while fostering a healthier global community.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring.